Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.

By Y. Nagata, K. Takayama, Y. Matsuo, Y. Norihisa, T. Mizowaki, T. Sakamoto, M. Sakamoto, M. Mitsumori, K. Shibuya, N. Araki and 2 more. International Journal of Radiation Oncology, Biology, Physics, 2005

673 citations recorded by the source corpus.

Subfields: Hepatology, Pulmonary and Respiratory Medicine, Radiation

View Paper: https://www.semanticscholar.org/paper/bde4df71bc732a0f511711569eb9f7d347f1486b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Fakiris
2. R. Timmerman
3. R. Mcgarry
4. L. Papiez
5. C. Yiannoutsos
6. Mark D. Williams
7. M. Henderson

Citations in the corpus

• Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. (2009, methodology): “For Stage IA lung cancer, OS rates after 1 year and 3 years were 92% and 83%, respectively, whereas for Stage IB lung cancer, OS rates were 82% and 72%, respectively (14).”